We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Cutting-Edge Medical Device Purifies and Concentrates Urine for Rapid Cancer Diagnosis

By LabMedica International staff writers
Posted on 03 Feb 2025
Print article
Image: The device has the potential for improving the early detection of various diseases (Photo courtesy of Bangor University)
Image: The device has the potential for improving the early detection of various diseases (Photo courtesy of Bangor University)

A groundbreaking medical device designed to purify and concentrate urine has the potential to revolutionize research and diagnosis of various health issues, including cancer.

Developed by Bee Robotics (based in Wales, UK) in collaboration with Bangor University (Gwynedd, UK), this prototype effectively processes urine to generate concentrated samples suitable for biological analysis. By collaborating with Bangor University, Bee Robotics was able to analyze and evaluate the automated procedure, resulting in more reliable test outcomes through the concentration and purification of urine samples. The automation aspect of this technology distinguishes it from traditional sample analysis methods, enabling faster processing times.

Complete automation minimizes the need for human involvement, marking a significant advancement in the diagnosis and research of various medical conditions. Although the research is still in its early phases, the scientific principles underlying the process have been a key focus for the team. Researchers intend to continue refining the methodology and advancing the prototype, which allows for sample concentration while minimizing inhibitors to improve the sensitivity of diagnostic tests.

Related Links:
Bangor University
Bee Robotics

Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Gold Member
Pharmacogenetics Panel
VeriDose Core Panel v2.0
New
Sample Transport Medium
UMMt RevolutioN 2
New
Biological Indicator Vials
BI-O.K.

Print article

Channels

Immunology

view channel
Image: The findings were based on patients from the ADAURA clinical trial of the targeted therapy osimertinib for patients with NSCLC with EGFR-activated mutations (Photo courtesy of YSM Multimedia Team)

Post-Treatment Blood Test Could Inform Future Cancer Therapy Decisions

In the ongoing advancement of personalized medicine, a new study has provided evidence supporting the use of a tool that detects cancer-derived molecules in the blood of lung cancer patients years after... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.